Inventor · disambiguated record
Amato J. Giaccia
Also filed as: GIACCIA AMATO · GIACCIA AMATO J
20 granted patents·23 pending applications·292 citations·filing 1992–2022
94Inventor score
Files withUNIV LELAND STANFORD JUNIOR28ELLIPSES PHARMA LTD2GIACCIA AMATO2GIACCIA AMATO J2AKSO BIOPHARMACEUTICAL INC1
Top patents by PatentIndex Score
43 records- 0195US6652849B2Anaerobe targeted enzyme mediated prodrug therapyUNIV LELAND STANFORD JUNIOR·Filed 2002·Granted Nov 25, 2003·59 cites·25 claims
- 0294US6984513B2Anaerobe targeted enzyme-mediated prodrug therapyUNIV LELAND STANFORD JUNIOR·Filed 2002·Granted Jan 10, 2006·75 cites·26 claims
- 0392US6416754B1Anaerobe targeted enzyme-mediated prodrug therapyUNIV LELAND STANFORD JUNIOR·Filed 1996·Granted Jul 9, 2002·74 cites·3 claims
- 0491US8618254B2Inhibition of AXL signaling in anti-metastatic therapyGIACCIA AMATO J·Filed 2012·Granted Dec 31, 2013·25 cites·8 claims
- 0590US10588938B2Receptor-based antagonists of the programmed cell death 1 (PD-1) pathwayUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Mar 17, 2020·8 cites·4 claims
- 0688US9074192B2Inhibition of AXL signaling in anti-metastatic therapyGIACCIA AMATO J·Filed 2012·Granted Jul 7, 2015·7 cites·7 claims
- 0783US9879061B2Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosisUNIV LELAND STANFORD JUNIOR·Filed 2012·Granted Jan 30, 2018·4 cites·4 claims
- 0879US11136563B2Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapyUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Oct 5, 2021·1 cites·6 claims
- 0979US10876176B2Antifibrotic activity of GAS6 inhibitorARAVIVE BIOLOGICS INC·Filed 2015·Granted Dec 29, 2020·2 cites·4 claims
- 1079US9266947B2Inhibition of AXL signaling in anti-metastatic therapyUNIV LELAND STANFORD JUNIOR·Filed 2013·Granted Feb 23, 2016·4 cites·6 claims
- 1178US9822347B2Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapyUNIV LELAND STANFORD JUNIOR·Filed 2013·Granted Nov 21, 2017·3 cites·3 claims
- 1276US2022409612A1Treatment of cancerELLIPSES PHARMA LTD·Filed 2022·Application pending·0 cites
- 1375US11498955B2SPD-1 variant# FC fusion proteinsUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Nov 15, 2022·1 cites·38 claims
- 1471US2022378873A1Receptor-based antagonists of the programmed cell death 1 (pd-1) pathwayUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 1569US2022220458A1Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic TherapyUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 1668US11400133B2Receptor-based antagonists of the programmed cell death 1 (PD-1) pathwayUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Aug 2, 2022·0 cites·20 claims
- 1767US2017065723A1Treatment of cancerCERULEAN PHARMA INC·Filed 2014·Application pending·0 cites
- 1865US9079859B2Synthetic lethal targeting of glucose transportIRWIN JOHN·Filed 2012·Granted Jul 14, 2015·1 cites·29 claims
- 1965US2023131056A1sPD-1 VARIANT – FC FUSION PROTEINSUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 2063US2019070169A1Treatment of cancerBLUELINK PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2161US2021060003A1Treatment of cancerELLIPSES PHARMA LTD·Filed 2020·Application pending·0 cites
- 2257US5646185ATumor treatment methodUNIV LELAND STANFORD JUNIOR·Filed 1993·Granted Jul 8, 1997·24 cites·18 claims
- 2356US2025115657A1Bispecific FC Fusion Proteins with sPD-1 and IL-15AKSO BIOPHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 2455US2022249522A1Hypoxia Targeting Compositions and Combinations Thereof with a PARP Inhibitor and Methods of Use ThereofUNIV LELAND STANFORD JUNIOR·Filed 2019·Application pending·0 cites
- 2552US2007021365A1Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating theretoUNIV LELAND STANFORD JUNIOR·Filed 2006·Application pending·0 cites
- 2651US2018094034A1Inhibition of axl/gas6 signaling in the treatment of liver fibrosisUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 2748US7378246B2Methods and compositions for regulating adipogenesisUNIV LELAND STANFORD JUNIOR·Filed 2003·Granted May 27, 2008·0 cites·11 claims
- 2848US2024294604A1sBCMA Variants and FC Fusion Proteins ThereofUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 2947US2015315552A1Inhibition of AXL Signaling in Primary Tumor TherapyUNIV LELAND STANFORD JUNIOR·Filed 2013·Application pending·0 cites
- 3047US2016266136A1High-affinity binding to gas6UNIV LELAND STANFORD JUNIOR·Filed 2013·Application pending·0 cites
- 3147US2007225242A1Method and composition for treating and preventing tumor metastasis in vivoUNIV LELAND STANFORD JUNIOR·Filed 2007·Application pending·0 cites
- 3247US2016108378A1Inhibition of AXL Signaling in Anti-Metastatic TherapyUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
- 3347US2018140679A1Modulation of axl receptor activity in combination with cytoreductive therapyUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 3447US2011105436A1Heteroaryl compounds, compositions, and methods of use in cancer treatmentAUCKLAND UNISERVICES LTD·Filed 2009·Application pending·0 cites
- 3544US9296732B2Substituted benzamides and their usesUNIV LELAND STANFORD JUNIOR·Filed 2013·Granted Mar 29, 2016·0 cites·7 claims
- 3643US8680064B2ShRNA gene therapy for treatment of ischemic heart diseaseWU JOSEPH C·Filed 2009·Granted Mar 25, 2014·0 cites·24 claims
- 3743US2013196907A1Promoting Erythropoietin, Erythrocyte, and Hematopoietic Stem Cell Production By Activating HIF In OsteoBlastsLELAND STANDFORD JUNIOR UNIVERSITY THE BOARD OF TRUSTEES OF·Filed 2011·Application pending·0 cites
- 3837US9085570B2Substituted benzamides and their usesGIACCIA AMATO·Filed 2011·Granted Jul 21, 2015·0 cites·9 claims
- 3937US2015329503A1Substituted benzamides and their usesUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
- 4034US2012225862A1Heteroaryl benzamides, compositions and methods of useSUTPHIN PATRICK D·Filed 2010·Application pending·0 cites
- 4133US2003044862A1Diagnostic marker for tumor hypoxia and prognosisUNIV LELAND STANFORD JUNIOR·Filed 2002·Application pending·0 cites
- 4232US2014315999A1Use of prolyl hydroxylase inhibitors as a radioprotective drug for the lower gastrointestinal tractGIACCIA AMATO·Filed 2012·Application pending·0 cites
- 4323US5346814AMethod of detecting cell response to cell-damaging energyUNIV LELAND STANFORD JUNIOR·Filed 1992·Granted Sep 13, 1994·4 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Amato J. Giaccia files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →